A snapshot of current genetic testing practice in Lynch syndrome: The results of a representative survey of 33 Latin American existing centres/registries

ROSSI, BENEDITO MAURO; VACCARO, CARLOS ALBERTO; CRUZ-CORREA, MARCIA; MINDIOLA, JORGE ANDRES RUGELES; BOHORQUEZ, MABEL; NASCIMENTO, IVANA; PETRACCHI, FLORENCIA; ROSSI, NORMA TERESA; PETTA-LAJUS, TIRZAH BRAZ; PEÑA, CARLOS MARIO MUÑETON; DEL MONTE, JULIO SÁNCHEZ; NEFFA, FLORENCIA; GOLUBICKI, MARIANO; FERRO, FABIANA ALEJANDRA; PIMENTA, CELIA APARECIDA MARQUES; CHÁVEZ, GUILIANA; SPIRANDELLI, ENRIQUE; FUENMAYOR, LUIS JOSÉ PALACIOS; HÉRITAS, NADIA CAMBADOS; VALLEJO, MICHAEL; JARAMILLO-KOUPERMANN, GABRIELA; DOMINGUEZ-BARRERA, CONSTANTINO; PLAZZER, JOHN-PAUL; MØLLER, PÅL; ROSSI, BENEDITO MAURO; VACCARO, CARLOS ALBERTO; CRUZ-CORREA, MARCIA; MINDIOLA, JORGE ANDRES RUGELES; BOHORQUEZ, MABEL; NASCIMENTO, IVANA; PETRACCHI, FLORENCIA; ROSSI, NORMA TERESA; PETTA-LAJUS, TIRZAH BRAZ; PEÑA, CARLOS MARIO MUÑETON; DEL MONTE, JULIO SÁNCHEZ; NEFFA, FLORENCIA; GOLUBICKI, MARIANO; FERRO, FABIANA ALEJANDRA; PIMENTA, CELIA APARECIDA MARQUES; CHÁVEZ, GUILIANA; SPIRANDELLI, ENRIQUE; FUENMAYOR, LUIS JOSÉ PALACIOS; HÉRITAS, NADIA CAMBADOS;

EUROPEAN JOURNAL OF CANCER

ELSEVIER SCI LTD

Año: 2019 vol. 119 p. 112 - 121

0959-8049

We aimed to assess the current genetics practice to manage patients with Lynch syndrome (LS) across Latin America. A Latin American LS survey was sent out to 52 centres/registries, comprising a total of 12 countries from the region. Overall, 33 centres completed the survey, of which the oldest LS registry was established in 1992 in Sao Paulo (Brazil), and the youngest this year in San Jose (Costa Rica). In total, 87% (26/30) of the participating centres/registries belonging to the nine countries are performing genetic testing. Overall, 1352 suspected families were sequenced. Pathogenic variants were identified in 34% of the families, with slightly differing distribution of variants between females and males. Path_MLH1 variants were identified in 39% of females and 50% of males (p = 0.023), while path_MSH2 were identified in 37% of females and males, followed by path_PMS2 in 11% of females and 8% of males, path_MSH6 in 13% of females and 3% of males (p < 0.001) and path_EPCAM in 0.3% of females and 2% of males. In Latin America, 9 of 12 (75%) participating countries had implemented healthcare for LS. LS screening is inconsistently applied within Latin America healthcare systems because of structural differences in the healthcare systems between the countries.